• BioLineRx Ltd., of Jerusalem, reported that preclinical results demonstrated that BL-7010, a polymer intended to treat celiac disease, reduced gluten toxicity and prevented gluten-induced pathological damage to the small intestine in rodents. The research was published in the February 2012 edition of Gastroenterology. Read More

VANCOUVER, British Columbia – The industry is redoubling its efforts to discover specific inhibitors of autophagy – the route by which cells degrade and recycle proteins – as evidence mounts from preclinical research and academic trials of the therapeutic potential of blocking that process. Read More

VANCOUVER, British Columbia – In the near future, Asian markets of the Pacific Rim region, including China, will contribute 40 percent of overall global pharmaceutical industry growth, which is expected to reach $156 billion annually by 2014, despite growing price interventions, according to Technology Visions Group LLC partner Robert Kilpatrick, who led a leadership session on Pacific Rim dealmaking at the BioPartnering North America conference. Read More

DUBLIN, Ireland – Shrugging off uncertainties stemming from a string of recent – and looming – patent expiries, Eli Lilly and Co. is investing €330 million (US$443 million) in a new biopharmaceutical production facility at its Dunderrow campus, which is located near Kinsale, in County Cork, Ireland. Read More

LONDON – While looking for a target that could be blocked to prevent the malaria parasite from multiplying in the blood of its human host, researchers serendipitously identified a molecule that stops the parasites from reproducing in the mosquito. Read More

LONDON – As the capital drought grinds on, charitable funding is throwing a lifeline to Europe's early stage biotechs, as the latest analysis of grants awarded by the Michael J. Fox Foundation (MJFF) illustrated. Read More